AbbVie Inc vs Invesco Solar ETF — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Invesco Solar ETF trades at $53.29. The key difference: AbbVie Inc pays a 2.79% dividend while Invesco Solar ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | TAN | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $73.95 |
52-Week Low | $197.38 | $36.62 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
TAN trades at $52.75, up 2.93% today amid positive solar sector news. Technical indicators are bearish overall, with moving averages signaling caution and RSI-6 suggesting overbought conditions. Recent tariffs on imported solar products have boosted sentiment, but the ETF faces headwinds from high volatility and regulatory uncertainty.
The outlook is mixed: supportive policies may drive growth, yet valuation concerns and interest rate sensitivity pose risks. Investors should weigh exposure to utility-scale solar growth against sector volatility and top-heavy holdings.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →